Immunovia AB (OSTO:IMMNOV) Tariff Resilience Score: 0/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IMMNOV Immunovia AB OSTO:IMMNOV
43 GF Score
Price kr0.18
GF Value kr0.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Tariff Resilience Score?

Immunovia AB has the Tariff Resilience Score of 0, which implies that the company might have .

Immunovia AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Immunovia AB might have .

Immunovia AB  (OSTO:IMMNOV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Immunovia AB Tariff Resilience Score Related Terms

OSTO:IMMNOV
43GF Score
Immunovia AB OSTO:IMMNOV
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of kr0.18 is trading 208% above its estimated GF Value™ of kr0.06. GuruFocus considers Immunovia AB to be Significantly Overvalued.

Key valuation signals for OSTO:IMMNOV:

  • Tariff Resilience Score: 0
  • GF Value™: kr0.06 vs. price of kr0.18 (208% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges 0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score

Get the complete analysis for OSTO:IMMNOV

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18
Price
kr0.06
GF Value